



Introduction to the GHIAA MAPGuide

Julie Barnes-Weise, JD, CLP
Executive Director, GHIAA

<https://ghiaa.org/mapguide-home/>

Overview



What is it?

The MAPGuide[®] is an open access tool for users to access & explore **analysis of provisions from global health agreements**.

It is organized into “issues” which are key areas of consideration for developing and rapidly concluding global health agreements with the aim of enabling increased global access to medical products.

Why did we develop it?

The 2014 Ebola outbreak in West Africa exposed significant gaps in pandemic preparedness, and the resources available to support response.

Agreements are an important tool in pandemic response because they create enforceable obligations for the development and supply of medical products. Transparency and knowledge of how those terms are included in agreements is essential to accelerating access.

MAPGuide Issues



Equitable Access

How do you ensure products are accessible & affordable to those in need?

Protecting & Sharing Information

What information must be shared confidentially? What must be made public?

Intellectual Property

Who owns the intellectual property? Who can use it and for what?

Term & Termination

Who can end the agreement and when? What happens when it ends?

Liability

Who is legally & financially responsible if something goes wrong?

Business Model

Who pays for what? How are key decisions made?

Search Options (1)



- **By Issue**
- **By Agreement Feature** - technology, development stage, partner type, agreement type
- **Advanced Search** - combination of issue & agreement feature

The screenshot shows the GHIA MAPGuide Home search interface. The main navigation bar includes the GHIA logo, 'MAPGuide Home', and a search input field with the placeholder 'Type key word'. Below the search bar are four filter categories: 'Browse Provision', 'By Issue', 'By Agreement Features', and 'Advanced Search'. The 'Advanced Search' filter is expanded, showing three columns of options:

- Select Issue or Sub-issues**
 - Equitable Access
 - All Equitable Access
 - Donation
 - Ensuring continuity
 - Access plans & principles
 - Preparedness & response
 - Affordable pricing
 - Territory access commitments
 - + Business model
 - + Protecting & sharing information
 - + Intellectual Property
 - + Liability
 - + Term & termination
- Agreement Type**
 - Any Agreement Types
 - License
 - Manufacturing
 - Other
 - Research & Development
 - Supply/Purchase
 - Technology Transfer
- Select Partner Type**
 - Any Partner types
 - Academic institution
 - Funder
 - Government
 - Industry
 - Multilateral organization
 - Product development partnership
- Select Development Stage**
 - Any Development stages
 - Discovery/Concept
 - Preclinical
 - Early clinical (through Phase 2)
 - Late clinical (Phase 3)
 - Commercialization
 - Field Testing
- Select Technology**
 - Any Technologies
 - Device
 - Diagnostic
 - Drug
 - Vaccine

A 'Search' button is located at the bottom of the expanded filter panel.

Search Options (2)



- **All Agreements** - [full list of agreements](#) and related provisions
- **Quick search** - type a keyword (e.g. COVID-19) into the search bar on the home page

MAPGuide Home Browse Provisions ▾ **All Agreements** Resources & Analysis

Learn More ▾

All Agreements

(Click + to show provisions)

Agreement title	Effective date	Partner type	Technology	Development stage	Agreement
+ Academic Institution - Company, Research Collaboration Agreement	2016	Academic institution Industry	Vaccine	Discovery/Concept Preclinical Early clinical (through Phase 2) Late clinical (Phase 3) Commercialization Field Testing	
+ AUTM Model Inter-Institutional Research Collaboration Agreement	2015	Academic institution	Device Diagnostic Drug Vaccine	Discovery/Concept Preclinical Early clinical (through Phase 2) Late clinical (Phase 3) Commercialization Field Testing	
+ AUTM Preliminary Patent Management Agreement	2013	Academic institution	Device Diagnostic Drug Vaccine	Discovery/Concept Preclinical Early clinical (through Phase 2) Late clinical (Phase 3) Commercialization Field Testing	
+ BARDA - Moderna, COVID-19 Vaccine Development Agreement	2020	Government Industry	Vaccine	Preclinical Early clinical (through Phase 2) Late clinical (Phase 3)	

MAPGuide Home Browse Provisions ▾ **All Agreements** Resources & Analysis

Learn More ▾

Quick Search

Search Results For:

Search results for:
• COVID-19

(Click + to show provisions)

Agreement title	Effective date	Partner type	Technology	Development stage
+ European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement	2020	Biotechnology company Government	Vaccine	Late clinical (Phase 3) Commercialization
+ European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement	2020	Government Multinational pharmaceutical company	Vaccine	Late clinical (Phase 3) Commercialization
+ UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement	2020	Government Multinational pharmaceutical company	Vaccine	Commercialization
+ US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement	2020	Biotechnology company Government	Vaccine	Preclinical Early clinical (through Phase 2) Late clinical (Phase 3)
+ Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement	2020	Biotechnology company Multinational pharmaceutical company	Vaccine	Discovery/Concept Preclinical Early clinical (through Phase 2) Late clinical (Phase 3)

Search Results For:

Search results for:
• COVID-19

(Click + to show provisions)


Agreement title	Effective date	Partner type
+ European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement	2020	Government Industry
+ European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement	2020	Government Industry

[Equitable Access](#) | [Donation](#)
[Equitable Access](#) | [Preparedness & response](#)
[Business model](#) | [Conflict of interest](#)
[Business model](#) | [Dispute resolution](#)
[Business model](#) | [Regulatory strategy](#)
[Business model](#) | [Payment structures](#)
[Business model](#) | [Product supply](#)
[Information & materials sharing](#) | [Confidentiality](#)
[Information & materials sharing](#) | [Information sharing](#)
[Intellectual Property](#) | [Exploitation of results](#)
[Intellectual Property](#) | [Ownership of results](#)
[Liability](#) | [Indemnification & liability](#)
[Liability](#) | [Representations & warranties](#)
[Term & termination](#) | [Effect of termination](#)
[Term & termination](#) | [Termination & withdrawal](#)

Limitations & Future Additions



- The MAPGuide should **not** be viewed as a ‘complete’ or ‘final’ data set.
 - We have a backlog of agreements to be analyzed and are continuously searching for new agreements.
 - There are many agreements that organizations are not required or willing to make publicly available.
- We encourage all organizations, whether public, private, academic or non-profit, to contribute agreements. We accept redacted & anonymized agreements, as well as extracts of relevant provisions. Contact comms@ghiaa.org.
- We are building a collection of [Commentaries](#) to explain and compare approaches to key issues based on provisions in the MAPGuide⁸.



Appendix: Reviewing MAPGuide Search Results

<https://ghiaa.org/mapguide-home/>

MAPGuide: Search Results



- **Results screen** - list of all agreements with a provision relevant to your search criteria. Click the **+** icon to view the list of provisions, then click a link to view an individual provision.
- **Provision** - divided into Context, Structural Questions, Summary of Approaches, Annotation, Provision Language, pop-up definitions.

MAPGuide Home
Learn More ▾
Browse Provisions ▾
All Agreements
Resources & Analysis

Search Results For:

Issue:
• Equitable Access | Ensuring continuity

(Click + to show provisions)

Agreement title	Effective date	Partner type	Technology	Development
+ US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement	2020	Biotechnology company Government	Vaccine	Preclinical Early clinical (t Late clinical (P
+ BMGF - CureVac, Global Access Commitments Agreement	2015	Biotechnology company Funder	Drug Vaccine	Early clinical (t Late clinical (P Commercializ Field Testing
+ CARB-X Research Subaward Agreement (for-profit)	2019	Funder General Industry	Device Diagnostic Drug Vaccine	Preclinical Early clinical (t
+ CEPI CfP3i Vaccine Funding Agreement Template	2018	Funder	Vaccine	Preclinical Early clinical (t

[Equitable Access | Ensuring continuity](#)

CEPI CfP3i Template Funding Agreement

Equitable Access | Ensuring continuity

Context

Source: Coalition for Epidemic Preparedness Innovations

Effective date: 2018

Partner type: Funder

Technology: Vaccine

Development stage: Preclinical
Early clinical (through Phase 2)

Agreement type: Template

Provision Language

17. Public Health License

17.1 Grant of a Public Health License. Awardee hereby grants the [Public Health License](#) to CEPI, on the condition that CEPI may only exercise the rights granted under the Public Health License in the following circumstances: (a) Awardee's activities supported by CEPI under the Project have meaningfully advanced the Product; (b) the Awardee has not notified CEPI that it wishes to terminate the Agreement pursuant to Clause 20.2; and (c) one or more of the triggers set out in Clause 17.2 has occurred.

17.2 Public Health License Triggers. Consistent with Clause 17.1, CEPI's right to exercise the Public Health License will be triggered when: (a) Awardee declines to participate in activities requested by CEPI under one or both of Clauses 16.2 or 16.3, (b) CEPI determines, in good faith, that Awardee will not be able to perform the activities under Clauses 16.2 or 16.3 if requested by CEPI; (c) thirty (30) days have passed since an [Outbreak Notice](#) and the Parties have not signed an agreement for the activities contemplated under Clauses 16.2 or 16.3, despite CEPI's request; or (d) the Agreement is terminated by CEPI pursuant to Clause 20.2, 20.3(a) or 20.3(c).

17.3 Agreement with Trusted Collaborator. In the event that the Public Health License becomes exercisable in accordance with Clause 17.1, CEPI may endeavor to reach agreement with a [Trusted Collaborator](#) to perform such activities as CEPI may deem necessary. If those negotiations do not result, or CEPI deems that such negotiations are unlikely to result, in an agreement, then CEPI may grant rights under its Public Health License to a third party unilaterally designated as a Trusted Collaborator by CEPI,

Context
Provision Language

Public Health License

A non-exclusive, fully paid-up, sublicensable and worldwide license under the Project Results and Enabling Rights to develop, manufacture, market and/or supply the Product worldwide; in each case for use in preparation for or response to an Outbreak or Increased Outbreak Preparation Need. For the purposes of this definition, the term "Product" shall mean the [Vaccine] in any form or dosage of pharmaceutical composition or preparation for use in humans.

Also see the definitions of "humanitarian license," "Outbreak," and "Increased Outbreak Preparation Need"

MAPGuide: Provisions



- **Context:** background information about the agreement.
- **Provision Language:** extract from the agreement section(s) relevant for the issue.
- **Structural Questions:** questions to consider when creating an agreement provision to address the issue.
- **Summary of Approaches:** overview of the approach taken to the issue & structural questions addressed in this agreement.
- **Annotations:** summary of the purpose of the agreement and any items of note.
- **Download Full Agreement:** for a PDF copy of the complete document.